Skip to main content

Research Repository

Advanced Search

All Outputs (9)

A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. (2023)
Journal Article
Ng, C., Dellschaft, N. S., Hoad, C., Marciani, L., Spiller, R., Crooks, C., …Smyth, A. R. (2023). A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. NIHR Open Research, 3(65), 1-16. https://doi.org/10.3310/nihropenres.13510.1

Background People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung fun... Read More about A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes..

Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis (2021)
Journal Article
Marsh, R., Gavillet, H., Hanson, L., Ng, C., Mitchell-Whyte, M., Major, G., …van der Gast, C. (2022). Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis. Journal of Cystic Fibrosis, https://doi.org/10.1016/j.jcf.2021.11.014

Background: Most people with cystic fibrosis (pwCF) suffer from gastrointestinal symptoms and are at risk of gut complications. Gut microbiota dysbiosis is apparent within the CF population across all age groups, with evidence linking dysbiosis to in... Read More about Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis.

Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis (2021)
Working Paper
Marsh, R., Gavillet, H., Hanson, L., Ng, C., Mitchell-Whyte, M., Major, G., …van der Gast, C. Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis

Background Most people with cystic fibrosis (pwCF) suffer from gastrointestinal symptoms and are at risk of gut complications. Gut microbiota dysbiosis is apparent within the CF population across all age groups, with evidence linking dysbiosis to int... Read More about Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis.

Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging (2021)
Journal Article
Ng, C., Dellschaft, N. S., Hoad, C. L., Marciani, L., Ban, L., Prayle, A. P., …Smyth, A. R. (2021). Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging. Journal of Cystic Fibrosis, 20(4), 591-597. https://doi.org/10.1016/j.jcf.2020.06.004

Background: Cystic fibrosis (CF) is a multi-system genetic disorder affecting >72,000 people worldwide. Most CF patients experience gastrointestinal symptoms and can develop complications. However, the mechanisms of CF gut disease are not well unders... Read More about Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging.

How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey (2020)
Journal Article
Smith, S., Rowbotham, N., Davies, G., Gathercole, K., Collins, S. J., Elliott, Z., …Smyth, A. (2020). How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey. BMJ Open Respiratory Research, 7(1), Article e000614. https://doi.org/10.1136/bmjresp-2020-000614

Introduction Relieving gastrointestinal (GI) symptoms was identified as a ‘top ten’ priority by our James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF). We conducted an online survey to find out more about the effect of GI sympto... Read More about How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey.

Treatment of pulmonary exacerbations in cystic fibrosis (2020)
Journal Article
Ng, C., Nadig, T., Smyth, A. R., & Flume, P. (2020). Treatment of pulmonary exacerbations in cystic fibrosis. Current Opinion in Pulmonary Medicine, 26(6), 679-684. https://doi.org/10.1097/mcp.0000000000000730

Purpose of review This review will discuss the challenges of defining a pulmonary exacerbations in cystic fibrosis and the key pathogens, which contribute. It will discuss the treatment options currently available and the importance of preventing... Read More about Treatment of pulmonary exacerbations in cystic fibrosis.

Persistent intestinal abnormalities and symptoms in cystic fibrosis: The underpinning mechanisms impacting gut health and motility. Protocol for a systematic review. (2020)
Other
Marsh, R. J., Ng, C., Major, G., Rivett, D. W., Smyth, A. R., & Gast, C. V. D. Persistent intestinal abnormalities and symptoms in cystic fibrosis: The underpinning mechanisms impacting gut health and motility. Protocol for a systematic review

Background Patients with cystic fibrosis (CF) are characterised by abnormalities of the intestinal tract relating to gut motility and physiological issues, with daily symptoms of disease including abdominal pain, flatulence, bloating, and constipatio... Read More about Persistent intestinal abnormalities and symptoms in cystic fibrosis: The underpinning mechanisms impacting gut health and motility. Protocol for a systematic review..

Smoking ban in cars protects children, but is vaping 'The Elephant in the Car'? (2020)
Journal Article
Ng, C., & Smyth, A. R. (2020). Smoking ban in cars protects children, but is vaping 'The Elephant in the Car'?. Thorax, 75(4), 297. https://doi.org/10.1136/thoraxjnl-2020-214660

In March 2006, smoking in public places was banned in Scotland. The following year a similar ban was introduced in England — the last of the UK home nations to adopt this policy. At the time, some suggested that the ban might paradoxically increase c... Read More about Smoking ban in cars protects children, but is vaping 'The Elephant in the Car'?.